List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 13 studies with search of:   "Hemosiderosis"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed A Study of Long-Term Treatment With Deferasirox in Patients With Beta-Thalassemia and Transfusional Hemosiderosis
Conditions: Beta-Thalassemia;   Hemosiderosis
Intervention: Drug: deferasirox
2 Recruiting ICL670 in Patients With Chronic Anemia and Transfusional Hemosiderosis
Conditions: Anemia;   Hemosiderosis
Intervention: Drug: Deferasirox (ICL670)
3 Recruiting Safety, Tolerability, and Efficacy of Deferasirox in MDS
Conditions: Myelodysplastic Syndromes;   Hemosiderosis
Intervention: Drug: Deferasirox
4 Completed Efficacy Study in Removing Excess Iron From the Heart
Conditions: Thalassemia Major;   Hemosiderosis
Interventions: Drug: Ferriprox (deferiprone);   Drug: Desferal (deferoxamine)
5 Recruiting Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
Conditions: Transfusional Iron Overload in the Heart;   Transfusional Hemosiderosis
Interventions: Drug: Deferasirox;   Drug: Deferoxamine
6 Active, not recruiting Extension Study on Efficacy and Safety of Deferasirox Treatment in Patients With Beta-Thalassemia and Transfusional Hemosiderosis
Condition: Beta-Thalassemia Major
Intervention: Drug: ICL670; deferasirox
7 Active, not recruiting A 1-Year Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Liver Iron Concentration of Deferasirox and Deferoxamine in Children and Adults With Sickle Cell Disease and Transfusional Hemosiderosis
Condition: Sickle Cell Disease
Intervention: Drug: Deferasirox
8 Completed Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
Condition: Anemia, Sickle Cell
Interventions: Drug: ICL670;   Drug: deferoxamine
9 Completed Safety & Efficacy of ICL670 Vs. Deferoxamine in Beta-Thalassemia Patients With Iron Overload Due to Blood Transfusions
Condition: Beta-Thalassemia
Interventions: Drug: ICL670;   Drug: deferoxamine
10 Recruiting ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
Condition: Anemia
Intervention: Drug: Deferasirox
11 Completed Study of Deferasirox in Iron Overload From Beta-Thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
Conditions: Beta-Thalassemia;   Myelodysplastic Syndromes;   Fanconi Syndrome;   Anemia, Diamond-Blackfan;   Anemia, Aplastic
Intervention: Drug: Deferasirox
12 Recruiting Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-Dependent Iron Overload
Conditions: Myelodysplastic Syndromes;   Transfusion Dependent Iron Overload
Intervention: Drug: ICL670/Deferasirox
13 Recruiting Efficacy and Safety of Oral Deferasirox (20 mg/kg/Day) in Patients Three to Six Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload
Condition: Iron Overload
Intervention: Drug: ICL670/Deferasirox

  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services